The effect of acenocoumarol on the antiplatelet effect of clopidogrel

Thrombosis and Haemostasis

Volumn 114, Issue 4, 2015, Pages 708-716

  Dewilde, Willem J M ^a   Janssen, Paul W A ^b   Bergmeijer, Thomas O ^b   Kelder, Johannes C ^b   Hackeng, Christian M ^b   ten Berg, Jurriën M ^b  

^a AMPHIA HOSPITAL   (Netherlands)

^b ST ANTONIUS HOSPITAL   (Netherlands)

Author keywords

Acenocoumarol; Clopidogrel; High on treatment platelet reactivity; Oral anticoagulation; Platelet aggregation; VerifyNow

Indexed keywords

ACENOCOUMAROL; CLOPIDOGREL; OMEPRAZOLE; PANTOPRAZOLE; PURINERGIC P2Y12 RECEPTOR; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; P2RY12 PROTEIN, HUMAN; PURINERGIC P2Y RECEPTOR ANTAGONIST; TICLOPIDINE;

ADULT; ARTICLE; ATRIAL FIBRILLATION; BLOOD CLOTTING PARAMETERS; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PLATELET REACTIVITY; PRIORITY JOURNAL; PROPENSITY SCORE; PROSPECTIVE STUDY; AGED; ANALOGS AND DERIVATIVES; BLOOD; CHI SQUARE DISTRIBUTION; DRUG EFFECTS; DRUG INTERACTION; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; NETHERLANDS; ODDS RATIO; POLYPHARMACY; REGISTER; RISK FACTOR; STATISTICAL MODEL; THROMBOCYTE; THROMBOCYTE AGGREGATION; VERY ELDERLY;

ACENOCOUMAROL; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; BLOOD PLATELETS; CHI-SQUARE DISTRIBUTION; DRUG INTERACTIONS; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NETHERLANDS; ODDS RATIO; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; POLYPHARMACY; PROPENSITY SCORE; PROSPECTIVE STUDIES; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RECEPTORS, PURINERGIC P2Y12; REGISTRIES; RISK FACTORS; TICLOPIDINE;

EID: 84943152679     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH15-02-0130     Document Type: Article

References (50)

1. Hamm CW, Bassand JP, Agewall S, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011; 32: 2999-3054.
2. Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol 2011; 58: e44-122.
3. Aradi D, Storey RF, Komócsi A, et al. Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. Eur Heart J 2014; 35: 209-215.
4. Stone GW, Witzenbichler B, Weisz G, et al. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet 2013; 382: 614-623.
5. Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009; 360: 354-362.
6. Sibbing D, Braun S, Morath T, et al. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol 2009; 53: 849-856.
7. Geisler T, Langer H, Wydymus M, et al. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur Heart J 2006; 27: 2420-2425.
8. Marcucci R, Gori AM, Paniccia R, et al. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a pointof-care assay: a 12-month follow-up. Circulation 2009; 119: 237-242.
9. Price MJ, Endemann S, Gollapudi RR, et al. Prognostic significance of postclopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J 2008; 29: 992-1000.
10. Bliden KP, DiChiara J, Tantry US, et al. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoingpercutaneous coronary intervention: is the current antiplatelet therapy adequate? J Am Coll Cardiol 2007; 49: 657-666.
11. Price MJ, Angiolillo DJ, Teirstein PS, et al. Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial. Circulation 2011; 124: 1132-1137.
12. Aradi D, Komocsi A, Vorobcsuk A, et al. Prognostic significance of high onclopidogrel platelet reactivity after percutaneous coronary intervention: systematic review and meta-analysis. Am Heart J 2010; 160: 543-551.
13. Sofi F, Marcucci R, Gori AM, et al. Clopidogrel non-responsiveness and risk of cardiovascular morbidity. An updated meta-analysis. Thromb Haemost 2010; 103: 841-848.
14. Breet NJ, van Werkum JW, Bouman HJ, et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. J Am Med Assoc 2010; 303: 754-762.
15. Kazui M, Nishiya Y, Ishizuka T, et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos 2010; 38: 92-99.
16. Savi P, Pereillo JM, Uzabiaga MF, et al. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost 2000; 84: 891-896.
17. Geisler T, Grass D, Bigalke B, et al. The residual platelet aggregation after deployment of intracoronary stent (PREDICT) score. J Thromb Haemost 2008; 6: 54-61.
18. Sibbing D, von Beckerath O, Schomig A, et al. Impact of body mass index on platelet aggregation after administration of a high loading dose of 600 mg of clopidogrel before percutaneous coronary intervention. Am J Cardiol 2007; 100: 203-205.
19. Collet JP, Hulot JS, Pena A, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 2009; 373: 309-317.
20. Gilard M, Arnaud B, Cornily JC, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (OmeprazoleCLopidogrel Aspirin) study. J Am Coll Cardiol 2008; 51: 256-260.
21. Siller-Matula JM, Spiel AO, Lang IM, et al. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J 2009; 157: 148.e1-5.
22. Tirkkonen T, Heikkilä P, Vahlberg T, et al. Epidemiology of CYP3A4-Mediated Clopidogrel Drug-Drug Interactions and Their Clinical Consequences. Cardiovasc Ther 2013; 31: 344-351.
23. Saw J, Steinhubl SR, Berger PB, et al. Clopidogrel for the Reduction of Events During Observation Investigators. Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial. Circulation 2003; 108: 921-924.
24. Siller-Matula JM, Lang I, Christ G, et al. Calcium-channel blockers reduce the antiplatelet effect of clopidogrel. J Am Coll Cardiol 2008; 52: 1557-1563.
25. Ojeifo O, Wiviott SD, Antman EM, et al. Concomitant Administration of Clopidogrel With Statins or Calcium Channel Blockers: Insights From the TRITONTIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38) Trial.ACC Cardiovasc Interv 2013; 6: 1275-1281.
26. Sibbing D, von Beckerath N, Morath T, et al. Oral anticoagulation with coumarin derivatives and antiplatelet effects of clopidogrel. Eur Heart J 2010; 31: 1205-1211.
27. Beinema M, Brouwers JR, Schalekamp T, et al. Pharmacogenetic differences between warfarin, acenocoumarol and phenprocoumon. Thromb Haemost 2008; 100: 1052-1057.
28. Ufer M. Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol.lin Pharmacokinet 2005; 44: 1227-1246.
29. Dewilde W, Verheugt FW, Breet N, et al. ’Ins’ and ’outs’ of triple therapy: Optimal antiplatelet therapy in patients on chronic oral anticoagulation who need coronary stenting. Netherl Heart J 2010; 18: 444-450.
30. Dewilde WJ, Oirbans T, Verheugt FW, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial.ancet 2013; 381: 1107-1115.
31. Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide Epidemiology of Atrial Fibrillation: A Global Burden of Disease 2010 Study. Circulation 2014; 129: 837-847.
32. Bonello L, Tantry US, Marcucci R, et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010; 56: 919-933.
33. Tantry US, Bonello L, Aradi D, et al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol 2013; 62: 2261-2273.
34. Ridgeway G, McCaffrey D, Morral A, et al. TWANG: Toolkit for Weighting and Analysis of Nonequivalent Groups. R package version 1.4-0. 18-3-2014. Available at: http: //CRAN.R-project.org/web/packages/twang. Last accessed 10-10-2014.
35. Breet NJ, Sluman MA, van Berkel MA, et al. Effect of gender difference on platelet reactivity. Neth Heart J 2011; 19: 451-457.
36. Elsenberg EH, van Werkum JW, van de Wal RM, et al. The influence of clinical characteristics, laboratory and inflammatory markers on ’high on treatment platelet reactivity’ as measured with different platelet function tests. Thromb Haemost 2009; 102: 719-727.
37. Bouman HJ, Harmsze AM, van Werkum JW, et al. Variability in on-treatment platelet reactivity explained by CYP2C19*2 genotype is modest in clopidogrel pretreated patients undergoing coronary stenting. Heart 2011; 97: 1239-1244.
38. Heestermans AA, van Werkum JW, Taubert D, et al. Impaired bioavailability of clopidogrel in patients with a ST-segment elevation myocardial infarction. Thromb Res 2008; 122: 776-781.
39. Bliden KP, Dichiara J, Lawal L, et al. The association of cigarette smoking with enhanced platelet inhibition by clopidogrel. J Am Coll Cardiol 2008; 52: 531-533.
40. Mangiacapra F, Bartunek J, Bijnens N, et al. Periprocedural variations of platelet reactivity during elective percutaneous coronary intervention. J. Thromb. Haemost 2012; 10: 2452-2461.
41. Ufer M, Svensson JO, Krausz KW, et al. Identification of cytochromes P450 2C9 and 3A4 as the major catalysts of phenprocoumon hydroxylation in vitro. Eur J Clin Pharmacol 2004; 60: 173-182.
42. Dewilde WJ, Janssen PW, Verheugt FW, et al. Triple Therapy for Atrial Fibrillation and Percutaneous Coronary Intervention: A Contemporary Review. J Am Coll Cardiol 2014; 64: 1270-1280.
43. Leadbeater PDM, Kirkby NS, Thomas S, et al. Aspirin has little additional antiplatelet effect in healthy volunteers receiving prasugrel. J Thromb Haemost 2011; 9: 2050-2056.
44. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045-1057.
45. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-2015.
46. Ferri N, Corsini A, Bellosta S. Pharmacology of the New P2Y12 Receptor Inhibitors: Insights on Pharmacokinetic and Pharmacodynamic Properties. Drugs 2013; 73: 1681-1709.
47. Sarafoff N, Martischnig A, Wealer J, et al. Triple therapy with aspirin, prasugrel, and vitamin K antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation. J Am Coll Cardiol 2013 21; 61: 2060-2066.
48. Lip GY, Windecker S, Huber K, et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Eur Heart J 2014; Epub ahead of print.
49. Windecker S, Kolh P, Alfonso F, et al 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2014; 35: 2541-2619.
50. Janssen PW, Ten Berg JM. Platelet function testing and tailored antiplatelet therapy. J Cardiovasc Transl Res 2013; 6: 316-328.